On July 25, 2019 Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse Biosciences" or the "Company"), a novel bioelectric medicine company bringing to market its proprietary CellFX System reported that the Company will report second quarter 2019 operational highlights and financial results on Thursday, August 8, 2019 (Press release, Pulse Biosciences, JUL 25, 2019, View Source [SID1234537764]). Pulse Biosciences management will host a conference call at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analysts and investors can participate in the conference call by dialing (844) 494-0190 (domestic) and (508) 637-5580 (international) using the conference ID# 9229379. The conference call can also be accessed live on the Investor Relations section of the Pulse Biosciences website at www.PulseBiosciences.com.

On July 25, 2019 IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, reported that it will hold a conference call and webcast on Friday, August 9, 2019 at 8:00 a.m. ET to discuss the company’s second quarter 2019 financial and operational results (Press release, IMV, JUL 25, 2019, View Source [SID1234537763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial analysts are invited to join the conference call by dialing (844) 461-9932 (U.S. and Canada) or (636) 812-6632 (international) using the conference ID: 7148568.

Other interested parties will be able to access the live audio webcast at this link: View Source The webcast will be recorded and available on the IMV website for 30 days following the call.

On July 25, 2019 Verastem, Inc. (NASDAQ: VSTM) operating as Verastem Oncology, (or "the Company"), reported their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology’s COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa (Press release, Verastem, JUL 25, 2019, View Source [SID1234537762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Verastem Oncology shall receive an upfront payment of $5 million USD. Verastem Oncology is also eligible to receive up to an additional $42 million USD in development and sales milestone payments, plus double-digit percentage royalties based on future net sales of COPIKTRA in the licensed territories. Sanofi will receive exclusive rights to develop and commercialize COPIKTRA, and hold the marketing authorization and product license for COPIKTRA, in the licensed territories. Sanofi will also have the right to collaborate with Verastem Oncology on certain global development and clinical trial activities.

"Sanofi brings world-class capabilities in developing and commercializing products, making them an ideal partner to bring COPIKTRA to patients in these territories," said Dan Paterson, President and Chief Operating Officer of Verastem Oncology. "Establishing this third partnership outside the U.S. validates the global potential of COPIKTRA and underscores our commitment to bring COPIKTRA to patients worldwide."

David Khougazian, Head of Sanofi Genzyme, China & Emerging Markets, commented, "As a specialty care leader, we welcome partnerships that have the potential to bring value for patients and caregivers. This agreement adds to our pipeline an oncology medicine with an innovative mechanism of action and a significant potential of new hope for the patients suffering from those types of blood malignancies with high unmet medical need. Partnering with Verastem Oncology for the development and commercialization of COPIKTRA is consistent with our goals to deliver enhanced patient care and to expand our presence in oncology in Emerging Markets."

COPIKTRA was approved in September 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. In addition, COPIKTRA has been granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Accelerated approval in FL was based on overall response rate and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. COPIKTRA includes a Boxed Warning for fatal and serious toxicities including infections, diarrhea or colitis, cutaneous reactions and pneumonitis. See full Prescribing Information for complete Boxed Warning and other important safety information.

On July 25, 2019 M2Gen, a health informatics solutions company focused on accelerating the discovery, development and delivery of precision medicine, reported a $3 million donation to fund seven team science research projects as part of the Oncology Research Information Exchange Network (ORIEN) New Oncologic Visionary Awards (NOVA) program (Press release, M2Gen, JUL 25, 2019, View Source [SID1234537761]). Each project will bring together researchers from a variety of leading cancer centers around the country, including ORIEN’s founding members, Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, to address some of cancer’s toughest questions. Each of the awarded projects are led by ORIEN Member institutions, an alliance of key oncology stakeholders dedicated to breaking down the silos that can inhibit discovery and progress. The ORIEN NOVA program was designed to advance research by encouraging collaborative multidisciplinary team science across the ORIEN members, allowing researchers to share information and expertise, to ultimately improve patient care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cancer is a complicated disease, and no single entity can solve it alone – innovative partnerships and access to data are the keys to answering cancer’s toughest questions," said William S. Dalton, PhD, MD, Executive Chair of M2Gen. "We’ve initiated the ORIEN NOVA program to give researchers and physician scientists the opportunity to access all of the resources of ORIEN’s research alliance, breaking down barriers between institutions to enable rapid learning and accelerate research efforts and discovery to bring new treatments to patients. Together with the Community Foundation of Tampa Bay, we have setup the ORIEN Foundation in March of this year to support future NOVA awards which will help facilitate ongoing research collaborations across ORIEN members for years to come."

More than 60 proposals were received from ORIEN cancer center faculty across the United States. Three ORIEN Avatar NOVA grants totaling $2 million and four ORIEN Investigator Initiated Proposal (IIP) NOVA grants totaling $1 million were selected after a scientific, peer-review of the proposed projects. Selected projects included those that demonstrated the potential for high-impact cancer research, as well as utilization of new data analytics and data acquisition tools. To view the full list of ORIEN Member recipients, please click here ORIEN NOVA.

"We are honored that our research project, led by Dr. Donghai Dai, was selected for the ORIEN NOVA grant, and grateful to M2Gen for their continued efforts to support collaborative research in the oncology field," said George Weiner, MD, Director of Holden Comprehensive Cancer Center. "We are eager to address the development of intra-tumor driver mutation prevalence and this funding gives us a runway to accelerate this valuable work."

"The future of science lies in collaboration and our team is thrilled to work alongside seven other leading cancer centers to advance Non-Hodgkin Lymphoma research as a result of ORIEN’s NOVA grant program," said Walter Curran Jr., MD, Executive Director of Winship Cancer Institute of Emory University.

Selected research projects were reviewed, scored and chosen by a scientific review panel consisting of ORIEN scientists and external researchers from cancer centers across the country.

For more information on ORIEN NOVA program, please visit View Source

If you are interested in supporting the ORIEN Foundation’s effort to accelerate cancer research, please visit the Community Foundation of Tampa Bay website: View Source

On July 25, 2019 AgilVax Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, reported that its Board of Directors has appointed Joseph Patti, PhD, to the position of President and Chief Executive Officer (Press release, Agilvax, JUL 25, 2019, View Source [SID1234537760]). Dr. Patti, the current Executive Chairman of the AgilVax Board of Directors, succeeds Federica Pericle, PhD, MBA, who resigned as President and CEO from the company to pursue another opportunity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ebetuel Pallares, PhD, AgilVax’s Chairman, said, "Agilvax has made great strides in advancing its therapeutic antibody-based programs toward the clinic and we continue to see tremendous potential in the technology to treat many different types of devastating cancers. We credit Federica for her scientific contributions, including building our versatile therapeutic antibody platform. Her creativity and intellectual contributions are assets and undoubtedly will continue to serve her well in her future endeavors."

Dr. Patti stated, "I’m honored to join the company at such an exciting time as it advances its xCT antibody-based therapeutics into human clinical trials. Data generated to date with the VLP-based AX09 and monoclonal antibodies validate the important biological role that xCT plays in various cancers. Our data, taken together with numerous scientific publications, strongly suggest that our antibody-based therapeutics in combination with chemotherapy, checkpoint and KRAS inhibitors could play a significant role in treating metastatic cancer."

About Joseph Patti, PhD

Dr. Patti has over twenty years of executive operating experience and played a critical role in raising over $300M in private and public equity. He led multiple R&D teams that successfully filed six Investigational New Drug Applications. Dr. Patti currently serves as President of JP Biotech Advisors, Inc., which provides strategic growth and drug development advice to emerging biotechnology companies. In May 2019, Dr. Patti was named a director at Armata Pharmaceuticals (NYSE: ARMP). Previously, Dr. Patti served as Aviragen Therapeutics’ (NASDAQ: AVIR) President and Chief Executive Officer. Before joining Aviragen, Dr. Patti co-founded Inhibitex, Inc. (NASDAQ: INHX) and served as its Chief Scientific Officer and Senior Vice President of Research and Development from 2007 until it was acquired by Bristol Myers Squibb (NYSE: BMS) in February 2012. Dr. Patti received a BS in Microbiology from the University of Pittsburgh, a MSPH from the University of Miami, School of Medicine and a PhD in Biochemistry from the University of Alabama at Birmingham.